The engineered expression of chimeric antigen receptors (CARs) on the surface of T cells
enables the redirection of T-cell specificity. Early clinical trials using CAR T cells for the …

Glioblastoma multiforme (GBM) is the most common and aggressive malignant tumor found
in the central nervous system. Currently, standard treatments in the clinic include maximal …

A patient with recurrent multifocal glioblastoma received chimeric antigen receptor (CAR)–
engineered T cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2 …

Purpose: A first-in-human pilot safety and feasibility trial evaluating chimeric antigen
receptor (CAR)–engineered, autologous primary human CD8+ cytotoxic T lymphocytes …

Malignant brain tumors, including glioblastoma, represent some of the most difficult to treat
of solid tumors. Nevertheless, recent progress in immunotherapy, across a broad range of …

Although chimeric antigen receptor (CAR) T cells have demonstrated signs of antitumor
activity against glioblastoma (GBM), tumor heterogeneity remains a critical challenge. To …

Glioblastoma (GB) is the most common and aggressive primary brain tumor in adults and
currently incurable. Despite multimodal treatment regimens, median survival in unselected …

High-grade gliomas are aggressive cancers that often become rapidly fatal. Immunotherapy
using CD8+ cytotoxic T lymphocytes (CTLs), engineered to express both herpes simplex …

T cell immunotherapy is emerging as a powerful strategy to treat cancer and may improve
outcomes for patients with glioblastoma (GBM). We have developed a chimeric antigen …

Glioblastoma (GBM) remains one of the most malignant primary tumors in adults, with a 5-
year survival rate less than 10% because of lacking effective treatment. Here, we aimed to …